With growing uncertainty in the trade environment, investors may delay new investments until policies become clearer.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from his new ...

In the early hours of September 14 2021, three men parked in a quiet car park in the southern English market town of Abingdon ...

In the early hours of September 14, 2021, three men parked in a quiet car park in the southern English market town of ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

State leaders are reviving talk of importing prescription drugs from Canada, even as US drugmakers and health-care attorneys ...

US President Donald Trump's executive order imposing a 10 percent tariff on Chinese imports is likely to drive up the cost of ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

President Trump’s tariffs in China are in place and hitting all products imported from the country — including a number of pharmaceutical drugs that Americans rely upon. Chinese imports ...

Trump initiated the sweeping tariffs to “hold Mexico, Canada, and China accountable to their promises of halting illegal ...

HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...